


LTURM34

Cat. No.:	HY-101667		
CAS No.:	1879887-96-3		
Molecular Formula:	C ₂₄ H ₁₈ N ₂ O ₃ S		
Molecular Weight:	414.48		
Target:	DNA-PK		
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 65 mg/mL (156.82 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.4127 mL	12.0633 mL	24.1266 mL
	5 mM	0.4825 mL	2.4127 mL	4.8253 mL
	10 mM	0.2413 mL	1.2063 mL	2.4127 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.25 mg/mL (7.84 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	LTURM34 is a specific DNA-PK inhibitor (IC ₅₀ =34 nM). LTURM34 exhibits 170-fold selectivity for DNA-PK over PI3K. LTURM34 shows potent antiproliferative activity in a wide range of tumor cell lines ^[1] .		
IC ₅₀ & Target	DNA-PK 34 nM (IC ₅₀)	PI3Kβ 5.8 μM (IC ₅₀)	PI4Kδ 8.5 μM (IC ₅₀)
In Vitro	LTURM34 shows potent inhibition of DNA-PK with excellent selectivity over the Class I PI3K isoforms. The IC ₅₀ s are 5.8 and 8.5 μM for PI3K β and δ, respectively. LTURM34 is more consistently active against the selected cell lines (11 of 16), but at best shows 54% inhibition against the HOP-92 non-small cell lung cancer line ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

PROTOCOL

Kinase Assay ^[1]

LTURM34 is dissolved at 10 mM in DMSO and stored at -20°C until use. PI3K enzyme activity is determined in 50 µL of 20 mM HEPES pH 7.5, 5 mM MgCl₂ with 180 µM PI and 10 µM ATP. After a 60 min incubation at room temperature the reaction is stopped by the addition of 50 µl of Kinase-Glo followed by a further 15 min incubation. Luminescence is then read using a luostar plate reader. LTURM34 is diluted in 20% (v/v) DMSO at the indicated concentrations in order to generate a concentration versus inhibition of enzyme activity curve which is then analysed using GraphPad Prism version 5.00 for Windows, in order to calculate the IC₅₀^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Biotechnol. 2023 Aug 3.
- Cell Rep. 2020 Jan 14;30(2):497-509.e4.
- Genome Res. 2021 Mar;31(3):461-471.
- Oncogenesis. 2020 Feb 3;9(2):8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Morrison R, et al. Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines. Eur J Med Chem. 2016 Mar 3;110:326-39.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA